Genetically Stable and Scalable Nanoengineering of Human Primary T Cells via Cell Mechanoporation-Reference-Cited by-同舟云学术

Genetically Stable and Scalable Nanoengineering of Human Primary T Cells via Cell Mechanoporation

Published:2023-07-28 Issue:16 Volume:23 Page:7341-7349
ISSN:1530-6984
Container-title:Nano Letters
language:en
Short-container-title:Nano Lett.

Author:

Hur Jeongsoo¹^ORCID,Kim Hyelee¹²^ORCID,Kim Uijin³,Kim Gi-Beom¹⁴^ORCID,Kim Jinho⁵,Joo Byeongju⁴^ORCID,Cho Duck⁵⁶,Lee Dong-Sung³,Chung Aram J.¹²⁴⁷^ORCID

Affiliation:

1. Department of Bioengineering, Korea University, Seoul 02841, Republic of Korea

2. Interdisciplinary Program in Precision Public Health (PPH), Korea University, Seoul 02841, Republic of Korea

3. Department of Life Sciences, University of Seoul, Seoul 02504, Republic of Korea

4. MxT Biotech, Seoul 04785, Republic of Korea

5. Department of Health Sciences and Technology, SAIHST, Sungkyunkwan University, Seoul 06355, Republic of Korea

6. Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 03063, Republic of Korea

7. School of Biomedical Engineering, Korea University, Seoul 02841, Republic of Korea

Funder

Samsung

National Research Foundation of Korea

Ministry of Trade, Industry and Energy

Institute for Information and Communications Technology Promotion

Ministry of SMEs and Startups

Publisher

American Chemical Society (ACS)

Subject

Mechanical Engineering,Condensed Matter Physics,General Materials Science,General Chemistry,Bioengineering

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.nanolett.3c01720

Reference47 articles.

1. CAR T cell immunotherapy for human cancer

2. Chimeric antigen receptor T-cell therapy — assessment and management of toxicities

3. Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia

4. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study

5. CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Digital Microfluidic Platform for the Microscale Production of Functional Immune Cell Therapies;2024-09-08

2. Current Advancements in Anti-Cancer Chimeric Antigen Receptor T Cell Immunotherapy and How Nanotechnology May Change the Game;International Journal of Molecular Sciences;2024-05-14

3. Non-viral delivery of RNA for therapeutic T cell engineering;Advanced Drug Delivery Reviews;2024-05

4. Enhanced Cellular Uptake through Nanotopography‐Induced Macropinocytosis;Advanced Functional Materials;2024-03-13

5. High throughput intracellular delivery by viscoelastic mechanoporation;Nature Communications;2024-01-02